Catherine Baucom
Surgery · Baton Rouge, LANPI 1588845184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Pfizer accounts for 61.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $80 and has fallen 81.8% since, to $14 in 2025. That places this record below the midpoint for surgery clinicians in LA, where the typical reported total is $1,529.
Across 16 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$161
- Hologic Sales And Service, LLC$33
- Organogenesis Inc.$15
- Veracyte, Inc.$15
- Elucent Medical$14
- Pacira Pharmaceuticals Incorporated$13
- plus $11 from 1 others
What the payments were for
- Food & beverage$262100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $161 |
| Hologic Sales And Service, LLC | 1 | $33 |
| Organogenesis Inc. | 1 | $15 |
| Veracyte, Inc. | 1 | $15 |
| Elucent Medical | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Merit Medical Systems Inc | 1 | $11 |
How this compares
$262 in reported general payments places this provider in the 20th percentile of 381 surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarestonToremifene Citrate | 33 | $14,061 |
| Letrozole | 170 | $4,051 |
| Anastrozole | 104 | $1,508 |
| Lorazepam | 56 | $571 |
| Ibandronate Sodium | 18 | $557 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $396 |
| Escitalopram Oxalate | 27 | $310 |
| Risedronate Sodium | 13 | $269 |
| Bupropion XlBupropion Hcl | 19 | $197 |
| Nystatin | 20 | $175 |
| Raloxifene Hcl | 14 | $170 |
| Ondansetron Hcl | 19 | $137 |
| Glipizide ErGlipizide | 11 | $132 |
| Alendronate Sodium | 27 | $109 |
| Alprazolam | 23 | $79 |
Paid to pharmacies, not to this prescriber.
Other surgery in Baton Rouge
- John TaborBaton Rouge$567K
- Mark HausmannBaton Rouge$250K
- Daryl MarxBaton Rouge$157K
- Tracee ShortBaton Rouge$108K
- Karl LeblancBaton Rouge$55K
- Karalyn BentleyBaton Rouge$42K
- Asif TalukderBaton Rouge$42K
- Joseph GriffinBaton Rouge$33K
- Mohammad Al EfishatBaton Rouge$22K
- Danielle CobbBaton Rouge$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.